Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 26 |
| Active Pipeline (Recruiting Now) | 18 (11) |
| Completed vs Stopped Early | 8 / 0 (0.0%) |
| Median Closed Actual Enrollment | 149 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| National Cancer Center Hospital | Chuo-ku, Tokyo | 4 |
| Mayo Clinic Florida | Jacksonville, FL | 4 |
| Osaka Metropolitan University Hospital | Osaka | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06948448 | A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus | Phase II | RECRUITING |
| NCT06579573 | ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. | Phase III | RECRUITING |
| NCT07429266 | INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) | Phase III | RECRUITING |
| NCT06936943 | ONO-4538 Study in Patients With Richter's Transformation | Phase II | RECRUITING |
| NCT06590896 | Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Ono Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.